MRKR on Nasdaq

Marker Therapeutics, Inc.

We are a clinical-stage immuno-oncology company specializing in the development of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications.1

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with CalAmp, Radiopharm Theranostics Ltd or Kala Pharmaceuticals (United States), or pick any stock.

  • TickerMRKR on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersHouston, Texas1
  • Incorporated inDE2
  • Business address2450 Holcombe Blvd, Tmc Partners Office 1.311, Houston, Tx 770212
  • Filer categoryNon-accelerated filer, Smaller reporting company2
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

We are a clinical-stage immuno-oncology company specializing in the development of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Harnessing millions of years of immunologic evolution, Marker’s Multi Antigen Recognizing (“MAR”)-T cell technology is designed to recognize and kill highly heterogeneous tumors without the need for genetic modifications. This approach selectively expands natural tumor-specific T cells from a patient’s/donor’s blood that are capable of recognizing a broad range of tumor associated antigens, or TAAs. Unlike other T cell therapies, MAR-T cells are able to recognize hundreds of different epitopes within up to six tumor-specific antigens to produce broad spectrum anti-tumor activity. Targeting multiple antigens simultaneously exploits the natural capacity of T cells to recognize and kill tumor target…3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-363.5%Operating margin4
-343.0%Net margin4
-46.2%Revenue growth, 20254
-72.4%Return on equity4

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Cancer Prevention And Research Institute Of Texas, Acute Myeloid Leukemia brought in 25% of the revenue Marker Therapeutics, Inc. broke down this way in fiscal 2025.

  1. Cancer Prevention And Research Institute Of Texas, Acute Myeloid Leukemia$900.0K425%down 80% from 2024
  2. National Institutes of Health Small Business Innovation Research For Lymphoma Grant$665.0K419%up 0% from 2024
  3. CPRIT Pancreatic Grant$574.0K416%
  4. National Institutes of Health Small Business Innovation Research$472.2K413%down 52% from 2024
  5. National Institutes of Health Small Business Innovation Research For Pancreatic Cancer$425.7K412%up 5831% from 2024
  6. National Institutes of Health National Cancer Institute Grant$391.3K411%up 6621% from 2024
  7. FDA Grant$118.5K43%down 77% from 2024
Products and services by year
Products and services20242025
Cancer Prevention And Research Institute Of Texas, Acute Myeloid Leukemia$4.4M$900.0K
National Institutes of Health Small Business Innovation Research For Lymphoma Grant$665.0K$665.0K
CPRIT Pancreatic Grant$574.0K
National Institutes of Health Small Business Innovation Research$982.2K$472.2K
National Institutes of Health Small Business Innovation Research For Pancreatic Cancer$7.2K$425.7K
National Institutes of Health National Cancer Institute Grant$5.8K$391.3K
FDA Grant$519.8K$118.5K

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Research and development100¢$11.8M
  • Income tax0¢$15.2K

Out of $3.5M in revenue.4 The company lost money this year.

Financial statements

Revenue56784$3.5M in 2025+1564% since 2019
0$2.0M$4.0M$6.0M$8.0M2019: $213.2K$213.2K20192020: $500.0K$500.0K2020+135%2021: $0$020212022: $3.5M$3.5M20222023: $3.3M$3.3M2023−6%2024: $6.6M$6.6M2024+99%2025: $3.5M$3.5M2025−46%
Operating income9610784-$12.9M in 2025−43% since 2019
-$40.0M-$30.0M-$20.0M-$10.0M02019: -$22.5M-$22.5M20192020: -$28.9M-$28.9M2020+28%2021: -$39.5M-$39.5M2021+37%2022: -$19.8M-$19.8M2022−50%2023: -$14.6M-$14.6M2023−26%2024: -$11.1M-$11.1M2024−24%2025: -$12.9M-$12.9M2025+16%
Net income9610784-$12.2M in 2025−43% since 2019
-$60.0M-$40.0M-$20.0M02019: -$21.4M-$21.4M20192020: -$28.7M-$28.7M2020+34%2021: -$41.9M-$41.9M2021+46%2022: -$29.9M-$29.9M2022−29%2023: -$8.2M-$8.2M2023−72%2024: -$10.7M-$10.7M2024+30%2025: -$12.2M-$12.2M2025+13%

Every line of the income statement as filed: the last 2 fiscal years, latest first.4

Period ending2025-12-312024-12-31
Total revenues$3.5M$6.6M
Research and development$11.8M$13.5M
General and administrative$4.2M$4.2M
Loss on early termination of vendor agreement$453.1K
Total operating expenses$16.4M$17.7M
Loss from operations-$12.9M-$11.1M
Interest income$594.2K$437.0K
Other income$117.4K
Loss from operations before income taxes-$12.2M-$10.7M
Income tax (benefit) expense-$15.2K$50.0K
Net loss-$12.2M-$10.7M
Net loss per share, basic (in dollars per share)-$0.79-$1.19
Net loss per share, diluted (in dollars per share)-$0.79-$1.19
Basic (in shares)15.3M shares9.0M shares
Diluted (in shares)15.3M shares9.0M shares

Compare Marker Therapeutics, Inc. with another company

Leadership

Who has led Marker Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Denis Corin2007–2009
  2. Glynn Wilson2011–2017
  3. Peter L. Hoang2017–2022
  4. Juan Vera2023–now

Chair

  1. Glynn Wilson2009–2011

President

  1. Denis Corin2007–2012
  2. John N. Bonfiglio2016–2017
  3. Peter L. Hoang2017–2022
  4. Juan Vera2023–now

Chief financial officer

  1. Patrick A. McGowan2007
  2. Tracy A. Moore2009
  3. Denis Corin2011
  4. Michael Loiacono2016–2018
  5. Anthony H. Kim2018–2022
  6. Eliot M. Lurier2023

Chief operating officer

  1. John N. Bonfiglio2016–2017
  2. Juan Vera2022–2023
2010201520202025
Board members and other officers (29)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • DirectorJohn Wilson named Dec 30, 202452

Former names

  • TAPIMMUNE INC.Jul 11, 2017 to Oct 17, 20182
  • TAPIMMUNE INCJul 3, 2007 to Jun 29, 20172
  • GENEMAX CORPJul 18, 2002 to Jun 28, 20072
  • EDUVERSE COMSep 29, 1999 to Jun 17, 20022

Timeline

  1. May 11, 2023New chief executive Juan Vera becomes CEO13
  2. Sep 25, 2017New chief executive Peter L. Hoang becomes CEO14
  3. Apr 5, 2011New chief executive Glynn Wilson becomes CEO15
  4. Jul 3, 2007New chief executive Denis Corin becomes CEO16

Filings

177 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 67 major events, 43 insider forms, 11 large holders, 1 private raises, 35 other. The latest 20:

  1. Aug 14, 202610-Q EDGAR
  2. May 15, 202610-Q EDGAR
  3. May 4, 20268-K EDGAR
  4. Mar 20, 2026DEFA14A EDGAR
  5. Mar 20, 2026ARS EDGAR
  6. Mar 20, 2026DEF 14A EDGAR
  7. Mar 19, 20268-K EDGAR
  8. Mar 18, 202610-K EDGAR
  9. Mar 10, 2026PRE 14A EDGAR
  10. Feb 9, 20268-K EDGAR
  11. Nov 19, 20254 PRIMARY DOCUMENT EDGAR
  12. Nov 19, 20254 PRIMARY DOCUMENT EDGAR
  13. Nov 19, 20254 OWNERSHIP DOCUMENT EDGAR
  14. Nov 17, 2025SCHEDULE 13D/A EDGAR
  15. Nov 14, 2025SCHEDULE 13G/A EDGAR
  16. Nov 14, 20258-K EDGAR
  17. Nov 13, 202510-Q EDGAR
  18. Nov 5, 20258-K EDGAR
  19. Nov 4, 20254 PRIMARY DOCUMENT EDGAR
  20. Nov 4, 20253 PRIMARY DOCUMENT EDGAR

The 177 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

2 open-market trades by officers, directors and large owners since October 2021: 2 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Dec 23, 2024ELMS STEVEDirectorBuy11,085$3.20$35.5KForm 4
Dec 23, 2024NEA Partners 16, L.P.10% ownerBuy554,250$3.20$1.8MForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Dec 23, 2024Raised $16.1 million in a private offering of equity Form D: 5 investors so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 35. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
NEA Management Company, LLC1,625,678$2.4M0.2%No change
Blue Owl Capital Holdings LP554,250$814.7K0.1%No change
Vanguard Capital Management LLC426,169$626.5K0.0%+36,850
Aisling Capital Management LP325,370$478.3K0.1%No change
Renaissance Technologies LLC249,423$366.7K0.0%+74,129
Geode Capital Management, LLC139,816$205.6K0.0%−21,094
Osaic Holdings, Inc.112,649$165.6K0.0%+19,528
Vanguard Fiduciary Trust Co87,269$128.3K0.0%No change
LPL Financial LLC83,147$122.2K0.0%+100
Concurrent Investment Advisors, LLC67,963$99.9K0.0%New
Two Sigma Investments, LP60,201$88.5K0.0%−800
XTX Topco Ltd45,357$66.7K0.0%−18,210
Northern Trust Corp34,629$50.9K0.0%+8,620
Citadel Advisors LLC32,517$47.8K0.0%New
State Street Corp20,948$30.8K0.0%No change
Invst, LLC18,000$26.5K0.0%−11,000
Creative Planning17,312$25.4K0.0%No change
Jane Street Group, LLC16,832$24.7K0.0%−19,471
Ashton Thomas Private Wealth, LLC16,400$24.1K0.0%No change
Fifth Third Bancorp10,000$14.7K0.0%No change
UBS Group AG8,150$12.0K0.0%−24,219
Vanguard Global Advisers, LLC2,512$3.7K0.0%No change
International Assets Investment Management, LLC2,000$2.9K0.0%No change
Tower Research Capital LLC (TRC)810$1.2K0.0%−2,327
Wells Fargo & Company/mn232$3410.0%No change

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57